Amgen’s T cell engager Imdelltra (tarlatamab) has gained FDA accelerated approval for an aggressive type of cell lung cancer that is notoriously difficult to treat.

The bispecific antibody is designed to bind both delta-like ligand 3 (DLL3) on small cell lung cancer (SCLC) cells and CD3 on T cells. Pharma companies have long considered DDL3 a promising target in oncology because healthy cells express it only in the cytoplasm, whereas 85–96% of SCLCs express it at high levels on the tumor cell surface. By binding DDL3 on the one hand and CD3 on T cells on the other, the T cell engager brings the patient’s own immune cells and cancer cells into physical proximity, enabling the activated T cells to attack and kill DLL3-expressing cancer cells.

安进 (Amgen) 的 T 细胞接合剂 Imdelltra (tarlatamab) 已获得 FDA 加速批准，用于治疗众所周知难以治疗的侵袭性细胞肺癌。

该双特异性抗体旨在结合小细胞肺癌 (SCLC) 细胞上的 δ 样配体 3 (DLL3) 和 T 细胞上的 CD3。制药公司长期以来一直认为 DDL3 是肿瘤学中一个有前途的靶点，因为健康细胞仅在细胞质中表达它，而 85-96% 的 SCLC 在肿瘤细胞表面高水平表达它。通过一方面结合 DDL3，另一方面结合 T 细胞上的 CD3，T 细胞接合器使患者自身的免疫细胞和癌细胞在物理上接近，使激活的 T 细胞能够攻击并杀死表达 DLL3 的癌细胞。